Evidence map›Paper›PMID 35579899›Full record

ArticleJAMA network open2022

Association of Congenital and Acquired Cardiovascular Conditions With COVID-19 Severity Among Pediatric Patients in the US.

Louis Ehwerhemuepha, Bradley Roth, Anita K Patel, Olivia Heutlinger, Carly Heffernan, Antonio C Arrieta, Terence Sanger, Dan M Cooper, Babak Shahbaba, Anthony C Chang and 4 more

Abstract readMulticenter Study
In one paragraph

Article in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Impacts of COVID-19 on pediatric patients with congenital heart disease: a small systematic and integrative literature review.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2025
    Pooled it
  2. Pooled it
  3. Observational
  4. Remdesivir in COVID-19: pros and cons.Frontiers in pharmacology · 2026
    Review
  5. Remdesivir in COVID-19: A Focus on Pediatric Cardiac Patients.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Review
  6. Article
  7. Antivirals in COVID-19: A Focus on Pediatric Cardiac Patients.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Louis EhwerhemuephaChildren's Health of Orange County, Orange, California.
Bradley RothUniversity of California-Irvine School of Medicine, Irvine.
Anita K PatelChildren's National Hospital System and George Washington University School of Medicine and Health Sciences, Washington, DC.
Olivia HeutlingerUniversity of California-Irvine School of Medicine, Irvine.
Carly HeffernanUniversity of California-Irvine School of Medicine, Irvine.
Antonio C ArrietaChildren's Health of Orange County, Orange, California.
Terence SangerChildren's Health of Orange County, Orange, California.
Dan M CooperUniversity of California-Irvine School of Medicine, Irvine.
Babak ShahbabaUniversity of California-Irvine School of Medicine, Irvine.
Anthony C ChangChildren's Health of Orange County, Orange, California.
William FeasterChildren's Health of Orange County, Orange, California.
Sharief TaramanChildren's Health of Orange County, Orange, California.
Hiroki MorizonoChildren's National Hospital System and George Washington University School of Medicine and Health Sciences, Washington, DC.
Rachel MaranoChildren's Health of Orange County, Orange, California.

Funding

Clinical and Translational Science Institute at Childrens NationalUL1TR001876 · NCATS · CHILDREN'S RESEARCH INSTITUTE · PI BELL, MICHAEL J · 2016 to 2021
$25.6M
Clinical and Translational Science Institute at Childrens National-Mentored Career Development CoreKL2TR001877 · NCATS · CHILDREN'S RESEARCH INSTITUTE · PI LUBAN, NAOMI L · 2016 to 2020
$2.0M
NCATS NIH HHS KL2 TR001877NCATS NIH HHS UL1 TR001876
6 · The paper itself

Abstract

Importance: Identifying the associations between severe COVID-19 and individual cardiovascular conditions in pediatric patients may inform treatment. Objective: To assess the association between previous or preexisting cardiovascular conditions and severity of COVID-19 in pediatric patients. Design, Setting, and Participants: This retrospective cohort study used data from a large, multicenter, electronic health records database in the US. The cohort included patients aged 2 months to 17 years with a laboratory-confirmed diagnosis of COVID-19 or a diagnosis code indicating infection or exposure to SARS-CoV-2 at 85 health systems between March 1, 2020, and January 31, 2021. Exposures: Diagnoses for 26 cardiovascular conditions between January 1, 2015, and December 31, 2019 (before infection with SARS-CoV-2). Main Outcomes and Measures: The main outcome was severe COVID-19, defined as need for supplemental oxygen or in-hospital death. Mixed-effects, random intercept logistic regression modeling assessed the significance and magnitude of associations between 26 cardiovascular conditions and COVID-19 severity. Multiple comparison adjustment was performed using the Benjamini-Hochberg false discovery rate procedure. Results: The study comprised 171 416 pediatric patients; the median age was 8 years (IQR, 2-14 years), and 50.28% were male. Of these patients, 17 065 (9.96%) had severe COVID-19. The random intercept model showed that the following cardiovascular conditions were associated with severe COVID-19: cardiac arrest (odds ratio [OR], 9.92; 95% CI, 6.93-14.20), cardiogenic shock (OR, 3.07; 95% CI, 1.90-4.96), heart surgery (OR, 3.04; 95% CI, 2.26-4.08), cardiopulmonary disease (OR, 1.91; 95% CI, 1.56-2.34), heart failure (OR, 1.82; 95% CI, 1.46-2.26), hypotension (OR, 1.57; 95% CI, 1.38-1.79), nontraumatic cerebral hemorrhage (OR, 1.54; 95% CI, 1.24-1.91), pericarditis (OR, 1.50; 95% CI, 1.17-1.94), simple biventricular defects (OR, 1.45; 95% CI, 1.29-1.62), venous embolism and thrombosis (OR, 1.39; 95% CI, 1.11-1.73), other hypertensive disorders (OR, 1.34; 95% CI, 1.09-1.63), complex biventricular defects (OR, 1.33; 95% CI, 1.14-1.54), and essential primary hypertension (OR, 1.22; 95% CI, 1.08-1.38). Furthermore, 194 of 258 patients (75.19%) with a history of cardiac arrest were younger than 12 years. Conclusions and Relevance: The findings suggest that some previous or preexisting cardiovascular conditions are associated with increased severity of COVID-19 among pediatric patients in the US and that morbidity may be increased among individuals children younger than 12 years with previous cardiac arrest.

Indexed as

COVID-19Heart ArrestAdolescentChildChild, PreschoolFemaleHospital MortalityHumansMaleRetrospective StudiesSARS-CoV-2

Identifiers

PMID35579899
PMCPMC9115618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.